22 Jul 2026
Key Takeaways from Market Study
The main drag is just as practical: FDA updated its Laboratory Developed Tests page in September 2025 after the March 2025 vacatur of the May 2024 LDT final rule
Fact.MR reports that the global non-invasive diagnostic tests market will expand from $1.3 Bn in 2026 to $3.8 Bn by 2036, an 11.3% CAGR. That represents an absolute dollar opportunity of $2.5 Bn. Imaging Diagnostics, Next-Generation Sequencing (NGS) and Oncology lead their respective segments today.
Fact.MR finds that doctors and laboratories choose non-invasive tests based on how well they fit into patient care. A test becomes useful when it reduces the need for tissue removal, speeds up diagnosis and gives doctors a clear way to track changes over time. Even with easier testing, accuracy still matters. Proper sample handling and clear reporting also decide whether the result is strong enough to guide care.
Imaging Diagnostics leads at 25.0% by Test Type, Next-Generation Sequencing (NGS) leads at 25.0% by Technology in 2026. Imaging Diagnostics holds 25.0% share in 2026. Next-Generation Sequencing (NGS) accounts for 25.0% share in 2026. Oncology represents 25.0% share in 2026.
The main difference comes from how each health system uses non-invasive testing. Countries with similar growth rates may depend on different tests, care settings and follow-up steps. Germany builds demand through university hospitals and specialist laboratories that can bring imaging, NGS and follow-up testing together. Brazil relies more on wider access to screening and strong referral services across public and private care. Easier tests have greater value when a positive result can move quickly into treatment. The USA benefits from large health systems that use AI-supported imaging with molecular tests. South Korea follows a hospital-based route in which connected hospitals share images, review patients from a distance and order molecular tests through the same network. The full study tracks these alongside markets across North America, Europe, Asia Pacific, Central and South America, and the Middle East amp Africa from 2026 to 2036.
FDA updated its Laboratory Developed Tests page in September 2025 after the March 2025 vacatur of the May 2024 LDT final rule. The update keeps oversight conditions visible for U.S. laboratories. A low-burden result has limited value when imaging slots and biopsy capacity are not ready with counseling access or treatment funding. Low-abundance signals are sometimes missed when the sample does not carry enough material for a confident result. Laboratories need sensitivity evidence before broad rollout.
Roche and Abbott provide a wide range of tests for hospitals and laboratories. Siemens Healthineers and GE HealthCare supply imaging systems, while Philips adds software for radiology work. Competition among these companies depends on proven results, hospital reach and how well their products fit into daily testing. Roche and Abbott lead broad diagnostics coverage, while Siemens Healthineers and GE HealthCare strengthen imaging-led non-invasive diagnostic pathways.
Clinicians look for tests that replace a specific invasive step. The result still needs a confirmation route that the hospital or laboratory has already funded. Staff and sample quality rules need to be defined before rollout. WHO stated in December 2024 that six in vitro diagnostic assessment sessions would take place in 2025 for dossiers and change requests. Through 2036, Hospitals and Laboratories should watch how the 11.3% forecast CAGR converts the $2.5Bn opportunity into orders, tracking the segment leaders above against the constraints already noted.
Beyond the headline forecast, the Fact.MR study segments the non-invasive diagnostic tests market by test type, technology, application, end user, and region. The study also compares country-level growth across North America, Europe, Asia Pacific, Central and South America, and the Middle East amp Africa from 2026 to 2036. It is built to help diagnostics developers, hospitals, and laboratory buyers see where demand is building, how rivals are positioned, and which opportunities are worth the investment.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
Non-Invasive Diagnostic Tests Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.